Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00352001 · OUTCOME

Overall Survival Among Patients With Complete Response

Lenalidomide and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndromes · Source last updated 2018-09-19

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
Full Range
Time frame
After 7 months of treatment, until the date of first documented myeloid leukemia or death, whichever came first, assessed up to 55 months

What was measured

Time (in months) patients who achieved a complete response using the RECIST criteria were alive on study

Analysis population: Only patients with complete response

Groups in this outcome

Lenalidomide and Azacitidine

azacitidine: Azacitidine subcutaneously once daily on days 1-5 or days 1-5 and 8-12. Treatment repeats every 28 days for up to 7 courses in the absence of relapse (after achieving complete or partial remission), disease progression, or unacceptable toxicity. lenalidomide: Oral lenalidomide once daily on days 1-14 or days 1-21.Treatment repeats every 28 days for up to 7 courses in the absence of relapse (after achieving complete or partial remission), disease progression, or unacceptable toxicity.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Lenalidomide and Azacitidine16

Reported measurements

Source class 1
Values in months · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
Lenalidomide and Azacitidine37Not reported755Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        7
        upper Limit
        55
        value
        37
denoms
  1. counts
    1. group Id
      OG000
      value
      16
    units
    Participants
description
Time (in months) patients who achieved a complete response using the RECIST criteria were alive on study
dispersion Type
Full Range
groups
  1. description
    azacitidine: Azacitidine subcutaneously once daily on days 1-5 or days 1-5 and 8-12. Treatment repeats every 28 days for up to 7 courses in the absence of relapse (after achieving complete or partial remission), disease progression, or unacceptable toxicity. lenalidomide: Oral lenalidomide once daily on days 1-14 or days 1-21.Treatment repeats every 28 days for up to 7 courses in the absence of relapse (after achieving complete or partial remission), disease progression, or unacceptable toxicity.
    id
    OG000
    title
    Lenalidomide and Azacitidine
param Type
MEDIAN
population Description
Only patients with complete response
reporting Status
POSTED
time Frame
After 7 months of treatment, until the date of first documented myeloid leukemia or death, whichever came first, assessed up to 55 months
title
Overall Survival Among Patients With Complete Response
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice